Skip to main content
PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients.  The Company was founded and is led by an experienced team of biotechnology founders and executives.

 

For questions regarding investment opportunities, email: investors@printbio.com

Learn More

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

| News, Press Releases | No Comments
PRNewsWire Link Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the…

Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses

| News | No Comments
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses

Pulmatrix and Eos merge to advance gerotherapeutics

| News | No Comments
Pulmatrix and Eos merge to advance gerotherapeutics